SDX-7320 plus eribulin for metastatic triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 2 study tests whether adding SDX-7320 to eribulin can work better for people with triple-negative metastatic breast cancer. It focuses on patients who have had prior chemotherapy and who also show signs of metabolic imbalance such as higher body weight or higher HbA1c.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have triple-negative metastatic breast cancer (estrogen/progesterone receptors ≤10% and HER2-negative).
- Your cancer is advanced/regionally recurrent or metastatic, and you have had up to 2 prior treatment lines for the advanced/metastatic setting.
- You have received anthracycline and taxane chemo before (or your doctor says you were not able to take them) and you can start eribulin.
- You must have metabolic dysfunction, such as HbA1c above 5.5 and/or a BMI of 30 or higher.
- Your body has to be strong enough for treatment (ECOG performance status of 0–1 and blood/liver/kidney numbers within limits).
- You must have measurable cancer or a mainly “lytic” bone lesion, and you’re willing to fast before treatment days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding trilaciclib to the chemotherapy drug eribulin can protect bone marrow and improve treatment for advanced triple-negative breast cancer. It may reduce side effects and help you tolerate treatment better.
This study tests whether adding a drug called everolimus to a targeted therapy called trastuzumab rezetecan is more effective than the targeted therapy alone for people with a specific type of triple-negative breast cancer (called LAR subtype) that has spread or come back. The combination aims to improve treatment response and potentially help you live longer.
This trial tests a new oral drug, BTX-9341, for people with advanced or metastatic hormone receptor-positive, HER2-negative breast cancer who have already had certain treatments, including a CDK4/6 inhibitor. The goal is to see if it is safe and effective.
This trial is testing a drug called eribulin (given alone or with other drugs) for people with advanced HER2-negative breast cancer that has already been treated with an ADC (antibody-drug conjugate). The goal is to see if this new treatment can help control the cancer and potentially shrink tumors.
This trial tests a combination of two cancer drugs (eribulin and anlotinib) for women whose breast cancer has spread and stopped responding to previous treatments, particularly antibody-drug conjugates. The study aims to see if this combination can help slow or shrink the cancer.
This trial tests a combination of three drugs for advanced breast cancer that is both hormone-receptor-positive and HER2-positive, and has stopped responding to a newer targeted therapy called T-DXd. The goal is to see if this new combo can shrink tumors or slow their growth.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.